Norepinephrine Transporter Imaging in Addiction Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2023-01-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study we propose to study 24 unmedicated abstinent alcohol dependent patients, 24 obese individuals and 24 individually matched healthy control subjects and determine Norepinephrine Transporter (NET) expression in vivo using (S,S)-\[11C\]MRB and PET.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm

NCT01699607

Nicotine Dependence Healthy

COMPLETED NA

Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET

NCT03527485

Opiate Dependence Cocaine Dependence

COMPLETED NA

Imaging the Neurochemistry of Drug Addiction With PET

NCT02817698

Smoking Cannabis

COMPLETED EARLY_PHASE1

Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence

NCT02994875

Cocaine Dependence

COMPLETED EARLY_PHASE1

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

NCT05011760

Cocaine Use Disorder

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study we propose to study 24 unmedicated abstinent alcohol dependent patients, 24 obese individuals and 24 individually matched healthy control subjects and determine NET expression in vivo using (S,S)-\[11C\]MRB and PET. This will provide novel insight into alterations in pre- and post-synaptic homeostasis in alcoholism and obese people with the goal to explain regulatory processes and their alterations in these disorders. A better understanding of brain mechanisms and contributory stress would have an enormous impact on the public's understanding of the vulnerabilities for these disorders, influence medical and legal response to these problems, could lead to a new understanding of these phenomena, and stimulate a better means of prevention and treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Alcohol Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

1. age 18-50 years inclusive;
2. able to read and write English;
3. for women, being in follicular phase of menstrual cycle at the time of the PET scan as determined by calculating the time since the last menses and assessments of serum hormone levels;
4. 30 \< BMI \< 35 for obese subjects (upper limit of 35 selected given our experience with heavier individuals fitting comfortably in the MRI scanner) and 18.5 \< BMI \<25 for normal weight subjects, and no recent weight changes in prior 12 weeks prior to the study;
5. for alcohol dependent patients meet current DSM-IV criteria for alcohol dependence or being in partial remission; abstinence on the MRI and PET scan days will be determined by patient self-report, breath alcohol tests (BACs) conducted during inpatient stay at the CNRU/GCRC, participants have to be non-obese BMI \< 30, and
6. for current daily smokers, having smoked 10 or more cigarettes daily for the past year and CO level \> 10 ppm at intake; for non-smokers, no tobacco consumption for more than one year and never having used tobacco daily.

2. use of any psychoactive medication within past three weeks;
3. any significant unstable medical condition such as asthma or heart disease which may limit the interpretation of the imaging results, for example due to changes in tracer delivery in hypertensive patients;
4. IQ\<70 based on past intelligence testing;
5. any metal in body that would pose a risk with MRI; and
6. claustrophobia that would interfere with MRI or PET imaging;
7. presence of alcohol and drug use in the 72 hours prior to scanning, with the exception of tobacco;
8. pregnancy or nursing for women,
9. peri- and post- menopausal women, and those with ovarectomies will be excluded
10. current eating disorders, including binge eating.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes